Medication info

Kojabeltan Tablet 150/12.5 mg

Prescription medicationTabletExpired
Ingredient · strength
Irbesartan›150mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Jongkundang Co., Ltd.
Appearance
Pink, biconvex, rectangular film-coated tablet
Packaging
30 tablets/bottle
Approval status
Expired

MFDS item code 201006871 · Notified 2010.11.17

This product's status changed to Expired on 2024.07.01. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension (inadequate control with monotherapy or need for initial combination therapy)
Who uses it
Adults · Children
Adult dosage
This medicine is administered once daily, regardless of meals. Dose titration for each component (irbesartan and hydrochlorothiazide) is recommended. ○ Adults 1. Patients whose blood pressure is not adequately controlled with monotherapy - For patients whose blood pressure is not adequately controlled with irbesartan 150 mg or hydrochlorothiazide alone, administer 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily. - For patients whose blood pressure is not adequately controlled with irbesartan 300 mg or irbesartan 150 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 12.5 mg once daily. - For patients whose blood pressure is not adequately controlled with irbesartan 300 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 25 mg once daily. Doses exceeding irbesartan 300 mg/hydrochlorothiazide 25 mg are not recommended. If necessary, this medicine may be administered in combination with other antihypertensive agents. 2. When this medicine is to be administered as initial therapy to patients with moderate or severe hypertension (stage 2), treatment should be individualized based on factors such as baseline blood pressure, target blood pressure, and the expected increase in the likelihood of achieving the treatment target compared with monotherapy. Typically, treatment is initiated with 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily; if blood pressure control is needed, the dose may be increased after 1 ~ 2 weeks up to a maximum of irbesartan 300 mg/hydrochlorothiazide 25 mg. Administration of this medicine as initial therapy is not recommended in patients with intravascular volume depletion. ○ Patients with renal impairment Because of the hydrochlorothiazide component, this medicine is not recommended for patients with severe renal impairment (creatinine clearance〈 30 mL/min). Loop diuretics are preferred in this patient population. No dosage adjustment is required for patients with renal impairment and a creatinine clearance of 30 mL/min or more. ○ Patients with volume depletion If sodium and/or fluid depletion is present, it should be corrected before administering this medicine. ○ Patients with hepatic impairment This medicine should not be used in patients with severe hepatic impairment. Thiazide drugs should be used with caution in patients with hepatic impairment. No dosage adjustment is required for patients with mild ~ moderate hepatic impairment. ○ Older adults No dosage adjustment is required for older adults.
Children's dosage
○ Pediatric Children and adolescents under 18 years of age

Ingredients

Manufacturer
Jongkundang Co., Ltd.

Efficacy & effects

Treatment of hypertension (inadequate control with monotherapy or need for initial combination therapy)

  • Hypertension
View approved original text

This medication is used as an additional treatment option for patients whose blood pressure is not adequately controlled with monotherapy. It is also utilized in initial therapy for patients with moderate to severe hypertension who require combination therapy to achieve target blood pressure. In other words, this medication is used for effective blood pressure management in cases where controlling blood pressure is difficult.

Dosage and Administration

Adult dosage

This medicine is administered once daily, regardless of meals. Dose titration for each component (irbesartan and hydrochlorothiazide) is recommended. ○ Adults 1. Patients whose blood pressure is not adequately controlled with monotherapy - For patients whose blood pressure is not adequately controlled with irbesartan 150 mg or hydrochlorothiazide alone, administer 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily. - For patients whose blood pressure is not adequately controlled with irbesartan 300 mg or irbesartan 150 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 12.5 mg once daily. - For patients whose blood pressure is not adequately controlled with irbesartan 300 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 25 mg once daily. Doses exceeding irbesartan 300 mg/hydrochlorothiazide 25 mg are not recommended. If necessary, this medicine may be administered in combination with other antihypertensive agents. 2. When this medicine is to be administered as initial therapy to patients with moderate or severe hypertension (stage 2), treatment should be individualized based on factors such as baseline blood pressure, target blood pressure, and the expected increase in the likelihood of achieving the treatment target compared with monotherapy. Typically, treatment is initiated with 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily; if blood pressure control is needed, the dose may be increased after 1 ~ 2 weeks up to a maximum of irbesartan 300 mg/hydrochlorothiazide 25 mg. Administration of this medicine as initial therapy is not recommended in patients with intravascular volume depletion. ○ Patients with renal impairment Because of the hydrochlorothiazide component, this medicine is not recommended for patients with severe renal impairment (creatinine clearance〈 30 mL/min). Loop diuretics are preferred in this patient population. No dosage adjustment is required for patients with renal impairment and a creatinine clearance of 30 mL/min or more. ○ Patients with volume depletion If sodium and/or fluid depletion is present, it should be corrected before administering this medicine. ○ Patients with hepatic impairment This medicine should not be used in patients with severe hepatic impairment. Thiazide drugs should be used with caution in patients with hepatic impairment. No dosage adjustment is required for patients with mild ~ moderate hepatic impairment. ○ Older adults No dosage adjustment is required for older adults.

Children's dosage

○ Pediatric Children and adolescents under 18 years of age

Precautions

This drug can cause serious harm to the fetus and newborn during pregnancy, so it must be discontinued immediately if pregnancy is confirmed. Women who are pregnant or capable of becoming pregnant, as well as nursing mothers, should not take this medication. Patients with allergies to this drug or its components, certain kidney diseases, liver diseases, or anuria should not take this medication. This drug may be inappropriate for patients with severely impaired kidney function, and those with mildly impaired kidney function should use it with caution. Caution is required in patients with certain conditions such as hypotension, renal artery stenosis, liver disorders, and heart valve disease. The hydrochlorothiazide component can increase the risk of skin cancer as it reacts sensitively to sunlight, making sunblock and skin monitoring necessary during use. Side effects such as dizziness, fatigue, nausea, and vomiting may occur during the use of this drug, so if any unusual symptoms arise, consultation with a healthcare professional is necessary. Kidney function and electrolyte status should be monitored regularly through blood tests to prevent imbalances of potassium and sodium. Caution is advised when driving or operating machinery due to possible dizziness or drowsiness. There may be interactions with other medications, so it is essential to inform healthcare providers of any medications being taken. Special caution is advised when used in combination with lithium, potassium supplements, certain diuretics, antihypertensives, and non-steroidal anti-inflammatory drugs (NSAIDs). Pregnant and nursing mothers should avoid using this drug, and it is not recommended for children and adolescents due to the lack of established safety and efficacy. Elderly patients may react more sensitively to this drug and should use it with caution. Overdose may lead to hypotension, electrolyte imbalances, dehydration symptoms, which require prompt treatment and appropriate management. This drug should be stored out of reach of children and kept in its original container; altering the container is discouraged to maintain drug quality.

Side effects

  • Dizziness
  • fatigue
  • nausea
  • vomiting
  • abnormal urination
  • elevated BUN
  • elevated creatine kinase
  • elevated creatinine
  • orthostatic dizziness
  • headache
Show 79 more
  • syncope
  • hypotension
  • tachycardia
  • edema
  • flushing
  • cough
  • diarrhea
  • dyspepsia
  • taste disturbance
  • jaundice
  • hepatitis
  • abnormal liver function
  • sexual dysfunction
  • changes in libido
  • kidney function impairment
  • limb edema
  • arthralgia
  • myalgia
  • tinnitus
  • vascular edema
  • rash
  • urticaria
  • hyperkalemia
  • decreased serum potassium
  • decreased serum sodium
  • headache
  • dizziness
  • tachycardia
  • shingles
  • colon cancer
  • hematoma
  • thrombocytopenia
  • depression
  • sleep disturbances
  • orthostatic hypotension
  • arrhythmia
  • aplastic anemia
  • bone marrow suppression
  • neutropenia
  • agranulocytosis
  • hemolytic anemia
  • leukopenia
  • thrombocytopenia
  • dyspnea
  • pancreatitis
  • loss of appetite
  • constipation
  • gastric irritation
  • sialadenitis
  • appetite loss
  • interstitial nephritis
  • renal dysfunction
  • transient blurred vision
  • xanthopsia
  • weakness
  • muscle spasms
  • anaphylactoid reaction
  • toxic epidermal necrolysis
  • necrotizing vasculitis
  • erythema multiforme-like reaction
  • erythema multiforme reactivation
  • photosensitivity reaction
  • fever
  • electrolyte imbalance
  • hyperuricemia
  • diabetes
  • hyperglycemia
  • elevated cholesterol
  • elevated triglycerides
  • hypokalemia
  • hyponatremia
  • hypochloremic alkalosis
  • hypomagnesemia
  • acute closed-angle glaucoma
  • hypotension
  • tachycardia
  • bradycardia
  • dehydration
  • muscle cramps

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air and moisture from entering, at a temperature between 1 degree and 30 degrees Celsius at room temperature. This helps maintain the effectiveness of the drug.

Appearance and packaging

Appearance

Pink, biconvex, rectangular film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.